ClinicalTrials.gg
CompletedNCT01995201Updated Jan 26, 2018Results posted

A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis

A Phase 3 interventional study of DMARD and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 53 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
19th of 113
401 · median 130
Started
2013
with 4 others
Phase 3
47 of 113
1 open now
Registered
76th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 19th largest by enrollment, is one of 5 that started in 2013, is one of 47 in phase 3, and was the 76th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter, open-label study will evaluate the efficacy and safety of subcutaneously administered RoActemra/Actemra (tocilizumab) as monotherapy or in combination with methotrexate or other non-biologic DMARDs in patients with active rheumatoid arthritis and an inadequate response to non-biologic DMARDs or to one anti-TNF. In Phase 1, all patients will receive RoActemra/Actemra 162 mg subcutaneously (sc) weekly for Weeks 1 to 24, with or without methotrexate or other non-biologic DMARDs. For Part 2, patients who achieve sustained clinical DAS28-ESR remission at Weeks 20 and 24 will be randomized to receive RoActemra/Actemra 162 mg sc either weekly or every 2 weeks for Weeks 24 to 48, with or without methotrexate or other non-biologic DMARDs. Patients who do not achieve sustained clinical remission but achieve low disease activity (DAS-ESR \</= 3.2) will continue the initial treatment of RoActemra/Actemra 162 mg sc weekly for Weeks 24 to 48, with or without methotrexate or other non-biologic DMARDs.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Active rheumatoid arthritis (DAS28-ESR > 3.2), according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria of > 6 months duration
  • Patients with intolerance or inadequate response to methotrexate or other non-biologic DMRADs or inadequate response to a first ant-TNF agent
  • Oral (\</= 10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for >/= 4 weeks prior to baseline
  • Permitted non-biologic DMRAD is allowed if at stable dose for at least 4 weeks prior to baseline
  • Females of and males with female partners of childbearing potential must be using a reliable means of as defined by protocol during the study and for at least 3 months following the last dose of RoActemra/Actemra
  • Patients with intolerance or inadequate response to methotrexate or other non-biologic DMARDs or inadequate response to first anti-TNF agent

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline
  • Rheumatic disease other than RA or significant systemic involvement secondary to RA; secondary Sjögren's syndrome with RA is permitted
  • Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16
  • Prior history of current inflammatory joint disease other than RA
  • Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline
  • Treatment with any agent with four weeks (or five-half lives of the investigational drug, whichever is longer) of screening
  • Intra-articular or parenteral within 4 weeks prior to baseline
  • Previous treatment with Abatacept
  • History of severe allergic of anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disease
  • History of diverticulitis, diverticulitis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforation
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis [TB] and atypical mycobacterial disease, and C, and herpes zoster, but excluding fungal infections or nail beds)
  • Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
  • Active TB requiring treatment within the previous 3 years
  • Positive hepatitis B or
  • Primary or secondary immunodeficiency (history of or currently active)
  • Evidence of active malignant disease, diagnosed with the previous 10 years (including hematological malignancies and solid tumors, except basal of squamous cell carcinoma of the skin diagnosed within the previous 20 years
  • Pregnant and lactating women
  • History of alcohol, drug, or chemical abuse within 1 year prior to screening
  • Neuropathies or other conditions that might interfere with pain evaluation
  • Inadequate hematological, real of liver function
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Part 1: All patients

    Drug: DMARD · Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]

  • Experimental
    Part 2 A: Sustained clinical remission

    Drug: DMARD · Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]

  • Experimental
    Part 2 B: Low disease activity

    Drug: DMARD · Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • DrugDMARD

    non-biological disease-modifying antirheumatic drugs at stable dose

  • stable dose

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    162 mg subcutaneously (SC) qw, Weeks 1-24

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    162 mg SC qw or q2w, Weeks 24-48

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    162 mg SC qw, Weeks 24-48

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24

    The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.

    Time frame: Week 20 and Week 24

Secondary outcomes

  1. Mean Change in Disease Activity Score 28 - Erythrocyte Sedimentation Rate(DAS28-ESR)

    The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.

    Time frame: From week 24 up to week 48

  2. Percentage of Patients Allocated in Groups A1 and A2 Who Remain With Clinical Remission Activity (DAS 28 ESR <2.6) up to Week 48

    The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.

    Time frame: From week 28 up to week 48

  3. Percentage of Patients Reporting Change in DAS 28 ESR >1.2 Until Week 48

    The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.

    Time frame: From week 28 up to week 48

  4. Percentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 24

    The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).

    Time frame: From week 2 until week 24

  5. Percentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 48

    The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).

    Time frame: From week 28 until week 48

  6. Number of Patients With Good and Moderate Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 24

    DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.

    Time frame: From week 2 until week 24

  7. Number of Patients With Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 48

    DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.

    Time frame: From week 28 until week 48

  8. Mean Change in Clinical Disease Activity Index (CDAI) From Baseline up to Week 24

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From baseline to Week 24

  9. Mean Change From Baseline in Clinical Disease Activity Index (CDAI) up to Week 48

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From week 24 until week 48

  10. Mean Change in Simplified Disease Activity Index (SDAI) From Baseline up to Week 24

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

    Time frame: From baseline to Week 24

  11. Mean Change in Simplified Disease Activity Index (SDAI) From Week 24 up to Week 48

    Simplified Disease Activity Index (SDAI) which is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

    Time frame: From week 24 until week 48

  12. Mean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 24

    TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.

    Time frame: From baseline to Week 24

  13. Mean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 48

    TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.

    Time frame: From week 24 until week 48

  14. Mean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 24

    SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.

    Time frame: From baseline to Week 24

  15. Mean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 48

    SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.

    Time frame: From week 24 until week 48

  16. Percentages of Patients Who Achieve DAS28-ESR Remission (DAS28 < 2.6) up to Week 48

    The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.

    Time frame: Week 48

  17. Percentages of Patients With Remission (CDAI<2.8) Until Week 24

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From baseline to Week 24

  18. Percentages of Patients With Remission (CDAI<2.8) Until Week 48

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From week 28 until week 48

  19. Percentages of Patients With Remission (SDAI<3.3) Until Week 24

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

    Time frame: From baseline to Week 24

  20. Percentages of Patients With Remission (SDAI<3.3) Until Week 48

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

    Time frame: From week 28 until week 48

  21. Percentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 24

    The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR is used to calculate the DAS28 score.

    Time frame: From baseline to Week 24

  22. Percentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 48

    The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR was used to calculate the DAS28 score.

    Time frame: From week 28 until week 48

  23. Percentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 24

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From baseline to Week 24

  24. Percentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 48

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From week 28 until week 48

  25. Percentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 24

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

    Time frame: From baseline to Week 24

  26. Percentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 48

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

    Time frame: From week 28 until week 48

  27. Safety: Number of Patients Reporting Adverse Events up to Week 24

    Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 24

    Time frame: From baseline to Week 24

  28. Safety: Number of Patients Reporting Adverse Events up to Week 48

    Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 48

    Time frame: From week 24 until week 48

  29. Immunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 24

    Number of patients resulting positive to anti-tocilizumab antibodies test are reported.

    Time frame: From baseline to Week 24

  30. Immunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 48

    Number of patients resulting positive to anti-tocilizumab antibodies test are reported.

    Time frame: From week 24 until week 48

  31. Immunogenicity: TCZ Levels up to Week 24

    Mean concentrations of TCZ in patients' blood are reported.

    Time frame: From baseline to Week 24

  32. Immunogenicity: TCZ Levels at Week 36 and Early Withdrawal Visit

    Mean concentrations of TCZ in patients' blood are reported.

    Time frame: week 36 and early withdrawal visit

  33. Immunogenicity: SIL-6R Levels up to Week 24

    Mean concentration of SIL-6R in patients' blood are reported.

    Time frame: From baseline to Week 24

  34. Immunogenicity: SIL-6R Levels at Week 36 and Early Withdrawal Visit

    Mean concentration of SIL-6R in patients' blood are reported.

    Time frame: Baseline, Week 36 and Early Withdrawal Visit

  35. Patient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 24

    This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.

    Time frame: From baseline to Week 24

  36. Patient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 48

    This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.

    Time frame: Baseline, from week 28 until week 48

  37. Assessment of Pain Reported by the Patient (VAS) Until Week 24

    This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".

    Time frame: From baseline to Week 24

  38. Assessment of Pain Reported by the Patient (VAS) Until Week 48

    This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".

    Time frame: Baseline, from week 28 until week 48

  39. Health Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 24

    The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.

    Time frame: From baseline to Week 24

  40. Health Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 48

    The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.

    Time frame: Baseline, from week 28 until week 48

  41. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 24

    The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.

    Time frame: From baseline to Week 24

  42. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 48

    The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.

    Time frame: Baseline, from week 28 until week 48

07

Results

Posted Jan 26, 2018

Participant flow

From Baseline Until Week 24
Participant flow — From Baseline Until Week 24
MilestonePhase 1: Tocilizumab MonotherapyPhase 1: Combination TherapyPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Started7432700000
Completed6428100000
Not completed104600000
Withdrew: Adverse event41500000
Withdrew: Anaphylaxis or hypersensitivity reaction0300000
Withdrew: Death0100000
Withdrew: Lack of efficacy2500000
Withdrew: Lost to follow-up2300000
Withdrew: Withdrawal by subject2800000
Withdrew: Physician decision0200000
Withdrew: Protocol violation0900000
From Week 24 Until Week 48
Participant flow — From Week 24 Until Week 48
MilestonePhase 1: Tocilizumab MonotherapyPhase 1: Combination TherapyPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Started00899095672
Completed00848989590
Not completed0051682
Withdrew: Adverse event0021131
Withdrew: Death0000020
Withdrew: Lack of efficacy0010021
Withdrew: Lost to follow-up0000110
Withdrew: Withdrawal by subject0010100
Withdrew: Physician decision0000100
Withdrew: Protocol violation0010200

Outcome measures

PrimaryPercentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24

The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.

Time frame:
Week 20 and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 2448.4 (35.75 to 61.27)52.9 (46.83 to 58.83)
Statistical analysis
  • Phase 1: Tocilizumab Monotherapy vs Phase 1: Combination Therapy · Chi-squared · p = 0.5231
SecondaryMean Change in Disease Activity Score 28 - Erythrocyte Sedimentation Rate(DAS28-ESR)

The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.

Time frame:
From week 24 up to week 48
Reported as:
Mean · mm/hr
Mean Change in Disease Activity Score 28 - Erythrocyte Sedimentation Rate(DAS28-ESR)
mm/hrPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 24-4.07 ± 1.03-4.01 ± 1.13
Week 28-3.94 ± 1.22-3.78 ± 1.31
Week 32-3.97 ± 1.38-3.77 ± 1.17
Week 36-3.82 ± 1.53-3.90 ± 1.16
Week 40-3.95 ± 1.26-3.84 ± 1.19
Week 44-4.05 ± 1.17-3.76 ± 1.17
Week 48-4.14 ± 1.24-3.68 ± 1.32
SecondaryPercentage of Patients Allocated in Groups A1 and A2 Who Remain With Clinical Remission Activity (DAS 28 ESR <2.6) up to Week 48

The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.

Time frame:
From week 28 up to week 48
Reported as:
Number · Percentage of participants
Percentage of Patients Allocated in Groups A1 and A2 Who Remain With Clinical Remission Activity (DAS 28 ESR <2.6) up to Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2888.5 (79.88 to 94.35)84.1 (74.75 to 91.02)
Week 3287.2 (78.27 to 93.44)81.1 (71.49 to 88.59)
Week 3680.2 (70.25 to 88.04)86.4 (77.39 to 92.75)
Week 4082.1 (72.26 to 89.65)80.7 (70.88 to 88.32)
Week 4489.0 (80.18 to 94.86)78.4 (68.35 to 86.47)
Week 4891.5 (83.20 to 96.50)73.9 (63.41 to 82.66)
SecondaryPercentage of Patients Reporting Change in DAS 28 ESR >1.2 Until Week 48

The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.

Time frame:
From week 28 up to week 48
Reported as:
Number · Percentage of participants
Percentage of Patients Reporting Change in DAS 28 ESR >1.2 Until Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2896.6 (90.25 to 99.28)96.6 (90.36 to 99.29)
Week 3296.5 (90.14 to 99.27)95.6 (89.01 to 98.78)
Week 3693.0 (85.43 to 97.40)97.7 (92.03 to 99.72)
Week 4098.8 (93.54 to 99.97)98.9 (93.83 to 99.97)
Week 4498.8 (93.39 to 99.97)95.5 (88.77 to 98.75)
Week 48100.0 (NA to NA)95.5 (88.77 to 98.75)
SecondaryPercentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 24

The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).

Time frame:
From week 2 until week 24
Reported as:
Number · Percentage of participants
Percentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
ACR20 - Week 227.0 (17.35 to 38.61)31.7 (26.59 to 37.08)
ACR20 - Week 450.7 (38.72 to 62.60)49.7 (44.00 to 55.37)
ACR20 - Week 867.1 (55.13 to 77.67)67.0 (61.36 to 72.30)
ACR20 - Week 1280.0 (68.73 to 88.61)74.7 (69.31 to 79.52)
ACR20 - Week 1679.7 (68.31 to 88.44)75.7 (70.35 to 80.49)
ACR20 - Week 2073.8 (61.46 to 83.97)81.0 (75.93 to 85.38)
ACR20 - Week 2479.7 (67.77 to 88.72)83.3 (78.39 to 87.44)
ACR20 - LOCF visit77.0 (67.77 to 88.72)79.0 (78.39 to 87.44)
ACR50 - week 29.5 (3.89 to 18.52)13.2 (9.66 to 17.38)
ACR50 - week 420.5 (11.98 to 31.62)25.3 (20.59 to 30.53)
ACR50 - week 837.0 (25.97 to 49.09)41.3 (35.70 to 47.14)
ACR50 - week 1251.4 (39.17 to 63.56)52.7 (46.84 to 58.51)
ACR50 - week 1653.6 (41.20 to 65.72)52.4 (46.50 to 58.25)
ACR50 - week 2058.5 (45.56 to 70.56)58.5 (52.48 to 64.24)
ACR50 - week 2459.4 (46.37 to 71.49)58.7 (52.72 to 64.53)
ACR50 - LOCF visit55.4 (46.37 to 71.49)54.2 (52.72 to 64.53)
ACR70 - week 25.4 (1.49 to 13.27)2.8 (1.30 to 5.29)
ACR70 - week 412.3 (5.80 to 22.12)10.6 (7.39 to 14.53)
ACR70 - week 817.8 (9.84 to 28.53)22.7 (18.05 to 27.83)
ACR70 - week 1232.9 (22.09 to 45.12)27.0 (22.05 to 32.47)
ACR70 - week 1629.0 (18.69 to 41.16)32.2 (26.87 to 37.88)
ACR70 - week 2033.8 (22.57 to 46.65)36.6 (31.01 to 42.52)
ACR70 - week 2440.6 (28.51 to 53.63)37.7 (32.03 to 43.67)
ACR70 - LOCF visit37.8 (28.51 to 53.63)33.9 (32.03 to 43.67)
ACR90 - week 21.4 (0.03 to 7.30)0.9 (0.19 to 2.72)
ACR90 - week 42.7 (0.33 to 9.55)1.6 (0.52 to 3.70)
ACR90 - week 86.8 (2.26 to 15.26)7.3 (4.65 to 10.89)
ACR90 - week 1212.9 (6.05 to 23.01)8.8 (5.82 to 12.61)
ACR90 - week 1613.0 (6.14 to 23.32)12.0 (8.49 to 16.27)
ACR90 - week 2013.8 (6.53 to 24.66)13.7 (9.95 to 18.29)
ACR90 - week 2423.4 (13.75 to 35.69)16.7 (12.56 to 21.61)
ACR90 - LOCF visit20.3 (13.75 to 35.69)15.0 (12.56 to 21.61)
SecondaryPercentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 48

The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).

Time frame:
From week 28 until week 48
Reported as:
Number · Percentage of participants
Percentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
ACR20 - Week 2890.0 (82.7 to 95.99)92.2 (84.63 to 96.82)
ACR20 - Week 3293.1 (85.59 to 97.43)94.4 (87.51 to 98.17)
ACR20 - Week 3684.9 (75.54 to 91.70)91.0 (83.05 to 96.04)
ACR20 - Week 4088.1 (79.19 to 94.14)93.2 (85.75 to 97.46)
ACR20 - Week 4491.5 (83.20 to 96.50)91.0 (83.05 to 96.04)
ACR20 - Week 4896.4 (89.92 to 99.26)88.8 (80.31 to 94.48)
ACR20 - LOCF visit95.5 (88.89 to 98.76)87.8 (79.18 to 93.74)
ACR50 - Week 2879.5 (69.61 to 87.40)81.1 (71.49 to 88.59)
ACR50 - Week 3285.1 (75.80 to 91.80)83.3 (74.00 to 90.36)
ACR50 - Week 3674.4 (63.87 to 83.22)83.1 (73.73 to 90.25)
ACR50 - Week 4079.8 (69.59 to 87.75)81.8 (72.16 to 89.24)
ACR50 - Week 4480.5 (70.26 to 88.42)78.7 (68.69 to 86.63)
ACR50 - Week 4888.1 (79.19 to 94.14)79.8 (69.93 to 87.55)
ACR50 - LOCF visit84.3 (75.02 to 91.12)78.9 (69.01 to 86.79)
ACR70 - Week 2859.1 (48.09 to 69.46)57.8 (46.91 to 68.12)
ACR70 - Week 3265.5 (54.56 to 75.39)54.4 (43.60 to 64.98)
ACR70 - Week 3661.6 (50.51 to 71.92)62.9 (52.03 to 72.93)
ACR70 - Week 4065.5 (54.31 to 75.52)59.1 (48.09 to 69.46)
ACR70 - Week 4467.1 (55.81 to 77.06)59.6 (48.62 to 69.83)
ACR70 - Week 4871.4 (60.53 to 80.76)65.2 (54.33 to 74.96)
ACR70 - LOCF visit68.5 (57.83 to 77.97)64.4 (53.65 to 74.26)
ACR90 - Week 2827.3 (18.32 to 37.81)32.2 (22.75 to 42.90)
ACR90 - Week 3235.6 (25.65 to 46.62)31.1 (21.77 to 41.74)
ACR90 - Week 3633.7 (23.88 to 44.72)30.3 (21.03 to 40.99)
ACR90 - Week 4041.7 (31.00 to 52.94)29.5 (20.29 to 40.22)
ACR90 - Week 4434.1 (24.03 to 45.45)27.0 (18.10 to 37.42)
ACR90 - Week 4845.2 (34.34 to 56.48)32.6 (23.02 to 43.34)
ACR90 - LOCF visit42.7 (32.26 to 53.63)32.2 (22.75 to 42.90)
SecondaryNumber of Patients With Good and Moderate Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 24

DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.

Time frame:
From week 2 until week 24
Reported as:
Number · Number of participants
Number of Patients With Good and Moderate Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 24
Number of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Good response - week 21461
Moderate response - week 236196
Good response - week 418109
Moderate response - week 449175
Good response - week 837162
Moderate response - week 832121
Good response - week 1241194
Moderate response - week 122795
Good response - week 1645209
Moderate response - week 162276
Good response - week 2045221
Moderate response - week 201856
Good response - week 2448225
Moderate response - week 241653
Good response - LOCF visit54247
Moderate response - LOCF visit1973
SecondaryNumber of Patients With Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 48

DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.

Time frame:
From week 28 until week 48
Reported as:
Number · Number of participants
Number of Patients With Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 48
Number of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Good response - week 288277
Moderate response - week 28510
Good response - week 327981
Moderate response - week 3269
Good response - week 367580
Moderate response - week 3698
Good response - week 407581
Moderate response - week 4097
Good response - week 447875
Moderate response - week 44413
Good response - week 487873
Moderate response - week 48415
Good response - LOCF visit8474
Moderate response - LOCF visit516
SecondaryMean Change in Clinical Disease Activity Index (CDAI) From Baseline up to Week 24

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From baseline to Week 24
Reported as:
Mean · CDAI score
Mean Change in Clinical Disease Activity Index (CDAI) From Baseline up to Week 24
CDAI scorePhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline values33.06 ± 12.4532.06 ± 12.28
Week 2-7.54 ± 9.57-8.62 ± 9.22
Week 4-13.03 ± 10.91-13.23 ± 10.65
Week 8-18.06 ± 11.05-18.46 ± 11.61
Week 12-21.56 ± 11.77-20.60 ± 11.42
Week 16-23.01 ± 12.33-21.79 ± 11.57
Week 20-24.07 ± 11.97-22.88 ± 12.10
Week 24-25.80 ± 13.31-23.43 ± 11.62
LOCF visit-24.42 ± 13.50-21.58 ± 12.85
SecondaryMean Change From Baseline in Clinical Disease Activity Index (CDAI) up to Week 48

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From week 24 until week 48
Reported as:
Mean · CDAI score
Mean Change From Baseline in Clinical Disease Activity Index (CDAI) up to Week 48
CDAI scorePhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline values29.27 ± 10.9029.64 ± 12.13
Week 24-25.54 ± 10.60-25.34 ± 12.10
Week 28-24.75 ± 10.64-24.01 ± 12.30
Week 32-24.56 ± 12.93-25.12 ± 11.64
Week 36-23.90 ± 11.56-25.45 ± 11.42
Week 40-25.16 ± 10.43-25.45 ± 11.75
Week 44-25.45 ± 10.11-25.26 ± 11.75
Week 48-26.44 ± 11.13-25.13 ± 12.51
LOCF visit-25.74 ± 11.29-24.87 ± 12.67
SecondaryMean Change in Simplified Disease Activity Index (SDAI) From Baseline up to Week 24

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

Time frame:
From baseline to Week 24
Reported as:
Mean · SDAI score
Mean Change in Simplified Disease Activity Index (SDAI) From Baseline up to Week 24
SDAI scorePhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline values48.66 ± 31.4844.40 ± 22.91
Week 2-20.45 ± 19.01-19.50 ± 18.75
Week 4-27.86 ± 23.54-24.34 ± 20.98
Week 8-32.61 ± 26.84-29.34 ± 21.96
Week 12-36.23 ± 27.04-30.95 ± 23.58
Week 16-37.82 ± 31.09-32.66 ± 22.79
Week 20-36.79 ± 25.47-33.95 ± 23.05
Week 24-41.38 ± 31.51-34.80 ± 22.44
LOCF visit-39.15 ± 30.45-32.73 ± 22.84
SecondaryMean Change in Simplified Disease Activity Index (SDAI) From Week 24 up to Week 48

Simplified Disease Activity Index (SDAI) which is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

Time frame:
From week 24 until week 48
Reported as:
Mean · SDAI score
Mean Change in Simplified Disease Activity Index (SDAI) From Week 24 up to Week 48
SDAI scorePhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline values41.45 ± 24.9040.92 ± 21.42
Week 24-37.02 ± 24.60-35.88 ± 20.71
Week 28-35.15 ± 25.90-34.50 ± 20.66
Week 32-35.60 ± 26.97-34.88 ± 20.53
Week 36-35.29 ± 26.55-35.35 ± 20.07
Week 40-37.26 ± 25.48-35.70 ± 19.80
Week 44-37.09 ± 25.17-35.06 ± 21.77
Week 48-37.93 ± 26.32-35.02 ± 21.74
LOCF visit-36.93 ± 25.75-34.69 ± 21.75
SecondaryMean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 24

TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.

Time frame:
From baseline to Week 24
Reported as:
Mean · TJC
Mean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 24
TJCPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline visit18.05 ± 12.9819.12 ± 13.38
Week 2-4.31 ± 7.56-5.00 ± 8.06
Week 4-7.04 ± 11.77-7.96 ± 9.43
Week 8-9.81 ± 10.37-10.90 ± 11.10
Week 12-12.27 ± 10.47-12.01 ± 10.88
Week 16-13.43 ± 12.35-13.09 ± 11.02
Week 20-13.65 ± 11.73-13.70 ± 11.48
Week 24-15.47 ± 13.35-14.20 ± 11.46
LOCF visit-14.36 ± 12.87-13.19 ± 11.75
SecondaryMean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 48

TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.

Time frame:
From week 24 until week 48
Reported as:
Mean · TJC
Mean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 48
TJCPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline values15.42 ± 9.0515.97 ± 12.77
Week 28-13.66 ± 8.44-12.88 ± 11.52
Week 32-13.40 ± 8.99-13.88 ± 11.43
Week 36-13.13 ± 8.82-13.78 ± 11.70
Week 40-14.06 ± 8.58-14.49 ± 12.07
Week 44-14.32 ± 8.25-13.93 ± 11.62
Week 48-14.40 ± 8.61-13.43 ± 12.17
LOCF visit-13.96 ± 8.68-13.27 ± 12.20
SecondaryMean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 24

SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.

Time frame:
From baseline to Week 24
Reported as:
Mean · SJC
Mean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 24
SJCPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline values10.05 ± 7.999.76 ± 6.64
Week 2-3.22 ± 4.40-3.42 ± 5.10
Week 4-5.07 ± 5.58-5.46 ± 5.41
Week 8-7.38 ± 6.47-6.81 ± 6.03
Week 12-7.93 ± 7.13-7.60 ± 6.00
Week 16-8.35 ± 7.71-8.01 ± 6.05
Week 20-8.72 ± 7.56-8.37 ± 6.50
Week 24-9.13 ± 7.66-8.38 ± 6.59
LOCF visit-8.47 ± 7.48-7.71 ± 6.67
SecondaryMean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 48

SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.

Time frame:
From week 24 until week 48
Reported as:
Mean · SJC
Mean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 48
SJCPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline values9.28 ± 6.529.23 ± 7.55
Week 28-8.64 ± 6.19-8.14 ± 6.81
Week 32-8.54 ± 7.02-8.62 ± 7.13
Week 36-8.48 ± 6.50-8.38 ± 6.76
Week 40-8.85 ± 6.40-8.51 ± 6.59
Week 44-8.73 ± 6.62-8.62 ± 6.97
Week 48-9.06 ± 6.58-8.72 ± 7.34
LOCF visit-8.82 ± 6.51-8.64 ± 7.33
SecondaryPercentages of Patients Who Achieve DAS28-ESR Remission (DAS28 < 2.6) up to Week 48

The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.

Time frame:
Week 48
Reported as:
Mean · Percentage of participants
Percentages of Patients Who Achieve DAS28-ESR Remission (DAS28 < 2.6) up to Week 48
Percentage of participantsPhase 2 Arm A1 - Monotherapy - qwPhase 2 Arm A1- Combination Therapy - qwPhase 2 Arm A2 - Monotherapy - q2wPhase 2 Arm A2 - Combination Therapy - q2w
Week 2882.6 (61.22 to 95.05)90.6 (80.70 to 96.48)87.0 (66.41 to 97.22)83.1 (71.73 to 91.24)
Week 3281.8 (59.72 to 94.81)89.1 (78.75 to 95.49)78.3 (56.30 to 92.54)82.1 (70.80 to 90.39)
Week 3690.5 (69.62 to 98.83)76.9 (64.81 to 86.47)86.4 (65.09 to 97.09)86.4 (75.69 to 93.57)
Week 4085.0 (62.11 to 96.79)81.3 (69.54 to 89.92)77.3 (54.63 to 92.18)81.8 (70.39 to 90.24)
Week 4494.7 (73.97 to 99.87)87.3 (76.50 to 94.35)77.3 (54.63 to 92.18)78.8 (66.98 to 87.89)
Week 48100 (NA to NA)89.1 (78.75 to 95.49)77.3 (54.63 to 92.18)72.7 (60.36 to 82.97)
LOCF Visit91.3 (71.96 to 98.93)89.4 (79.36 to 95.63)73.9 (51.59 to 89.77)73.1 (60.90 to 83.24)
SecondaryPercentages of Patients With Remission (CDAI<2.8) Until Week 24

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From baseline to Week 24
Reported as:
Number · Percentage of participants
Percentages of Patients With Remission (CDAI<2.8) Until Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline visit0 (0 to 0)0 (0 to 0)
Week 22.7 (0.33 to 9.42)1.6 (0.51 to 3.62)
Week 42.7 (0.33 to 9.55)5.1 (2.96 to 8.19)
Week 811.0 (4.85 to 20.46)14.4 (10.61 to 18.88)
Week 1215.7 (8.11 to 26.38)19.3 (14.92 to 24.22)
Week 1618.8 (10.43 to 30.06)22.8 (18.06 to 28.02)
Week 2027.7 (17.31 to 40.19)26.8 (21.70 to 32.31)
Week 2429.7 (18.91 to 42.42)30.2 (24.93 to 35.99)
LOCF visit29.7 (19.66 to 41.48)29.4 (24.48 to 34.62)
SecondaryPercentages of Patients With Remission (CDAI<2.8) Until Week 48

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From week 28 until week 48
Reported as:
Number · Percentage of participants
Percentages of Patients With Remission (CDAI<2.8) Until Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2846.6 (35.88 to 57.54)48.3 (37.59 to 59.16)
Week 3248.3 (37.42 to 59.25)45.6 (35.02 to 56.40)
Week 3652.3 (41.27 to 63.21)46.6 (35.88 to 57.54)
Week 4052.4 (41.19 to 63.40)45.5 (34.80 to 56.42)
Week 4450.0 (38.75 to 61.25)50.6 (39.75 to 61.33)
Week 4859.0 (47.69 to 69.72)53.9 (43.04 to 64.56)
LOCF Visit57.8 (46.91 to 68.12)60.3 (52.77 to 67.56)
SecondaryPercentages of Patients With Remission (SDAI<3.3) Until Week 24

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

Time frame:
From baseline to Week 24
Reported as:
Number · Percentage of participants
Percentages of Patients With Remission (SDAI<3.3) Until Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline visit0 (0 to 0)0 (0 to 0)
Week 21.4 (0.04 to 7.50)1.9 (0.71 to 4.14)
Week 42.9 (0.35 to 9.94)4.8 (2.72 to 7.83)
Week 811.1 (4.92 to 20.72)14.6 (10.75 to 19.13)
Week 1214.3 (7.07 to 24.71)18.8 (14.47 to 23.72)
Week 1617.4 (9.32 to 28.41)22.2 (17.56 to 27.47)
Week 2028.1 (17.60 to 40.76)25.8 (20.77 to 31.36)
Week 2431.7 (20.58 to 44.69)28.8 (23.53 to 34.49)
LOCF visit28.4 (18.50 to 40.05)25.4 (20.75 to 30.46)
SecondaryPercentages of Patients With Remission (SDAI<3.3) Until Week 48

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

Time frame:
From week 28 until week 48
Reported as:
Number · Percentage of participants
Percentages of Patients With Remission (SDAI<3.3) Until Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2850.0 (39.02 to 60.98)46.0 (35.23 to 57.00)
Week 3248.8 (37.90 to 59.86)45.6 (35.02 to 56.40)
Week 3653.5 (42.41 to 64.32)47.7 (36.96 to 58.65)
Week 4055.4 (44.10 to 66.34)44.3 (33.73 to 55.30)
Week 4450.0 (38.75 to 61.25)47.2 (36.51 to 58.06)
Week 4852.4 (41.11 to 63.59)47.7 (36.96 to 58.65)
LOCF Visit51.7 (40.48 to 62.41)47.8 (37.13 to 58.57)
SecondaryPercentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 24

The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR is used to calculate the DAS28 score.

Time frame:
From baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Week 221.6 (12.89 to 32.72)21.5 (17.12 to 26.47)
Week 426.0 (16.45 to 37.62)36.8 (31.39 to 42.41)
Week 850.7 (38.72 to 62.60)55.4 (49.54 to 61.16)
Week 1258.6 (46.17 to 70.23)67.7 (62.01 to 73.00)
Week 1666.7 (54.29 to 77.56)72.4 (66.89 to 77.48)
Week 2067.7 (54.95 to 78.77)78.2 (72.91 to 82.83)
Week 2475.0 (62.60 to 84.98)81.1 (75.98 to 85.49)
LOCF visit73.0 (61.39 to 82.65)74.0 (68.90 to 78.68)
SecondaryPercentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 48

The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR was used to calculate the DAS28 score.

Time frame:
From week 28 until week 48
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2895.4 (88.64 to 98.73)88.6 (80.09 to 94.41)
Week 3291.9 (83.95 to 96.66)92.2 (84.63 to 96.82)
Week 3687.2 (78.27 to 93.44)92.0 (84.30 to 96.74)
Week 4089.3 (80.63 to 94.98)92.0 (84.30 to 96.74)
Week 4496.3 (89.68 to 99.24)87.5 (78.73 to 93.59)
Week 4895.1 (87.98 to 98.66)86.4 (77.39 to 92.75)
LOCF Visit94.4 (87.37 to 98.15)85.6 (76.57 to 92.08)
SecondaryPercentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 24

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Week 213.5 (6.68 to 23.45)16.9 (12.98 to 21.50)
Week 424.7 (15.32 to 36.14)26.9 (22.08 to 32.21)
Week 841.1 (29.71 to 53.23)47.5 (41.71 to 53.32)
Week 1257.1 (44.75 to 68.91)52.4 (46.51 to 58.17)
Week 1662.3 (49.83 to 73.71)60.7 (54.81 to 66.35)
Week 2066.2 (53.35 to 77.43)65.1 (59.29 to 70.68)
Week 2471.9 (59.24 to 82.40)66.9 (61.07 to 72.38)
LOCF visit66.2 (54.28 to 76.81)61.2 (55.64 to 66.48)
SecondaryPercentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 48

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From week 28 until week 48
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2886.4 (77.39 to 92.75)85.4 (76.32 to 91.99)
Week 3289.7 (81.27 to 95.16)86.7 (77.87 to 92.92)
Week 3680.2 (70.25 to 88.04)89.8 (81.47 to 95.22)
Week 4086.9 (77.78 to 93.28)88.6 (80.09 to 94.41)
Week 4489.0 (80.18 to 94.86)85.4 (76.32 to 91.99)
Week 4892.8 (84.93 to 97.30)87.6 (78.96 to 93.67)
LOCF Visit91.0 (83.05 to 96.04)87.8 (79.18 to 93.74)
SecondaryPercentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 24

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

Time frame:
From baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 24
Percentage of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Week 216.7 (8.92 to 27.30)17.6 (13.56 to 22.32)
Week 427.1 (17.20 to 39.10)28.3 (23.36 to 33.65)
Week 841.7 (30.15 to 53.89)48.1 (42.31 to 54.00)
Week 1258.6 (46.17 to 70.23)55.6 (49.74 to 61.41)
Week 1663.8 (51.31 to 75.01)62.5 (56.63 to 68.11)
Week 2065.6 (52.70 to 77.05)66.3 (60.43 to 71.83)
Week 2474.6 (62.06 to 84.73)67.3 (61.41 to 72.75)
LOCF visit63.5 (51.51 to 74.40)56.9 (51.32 to 62.32)
SecondaryPercentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 48

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.

Time frame:
From week 28 until week 48
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 48
Percentage of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Week 2884.9 (75.54 to 91.70)83.89 (74.48 to 90.91)
Week 3289.5 (81.06 to 95.10)85.6 (76.57 to 92.08)
Week 3679.1 (68.95 to 87.10)87.5 (78.73 to 93.59)
Week 4086.7 (77.52 to 93.19)86.4 (77.39 to 92.75)
Week 4491.5 (83.20 to 96.50)82.0 (72.45 to 89.36)
Week 4893.9 (86.34 to 97.99)81.8 (72.16 to 89.24)
LOCF Visit91.0 (83.05 to 96.04)81.1 (71.49 to 88.59)
SecondarySafety: Number of Patients Reporting Adverse Events up to Week 24

Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 24

Time frame:
From baseline to Week 24
Reported as:
Number · Number of participants
Safety: Number of Patients Reporting Adverse Events up to Week 24
Number of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Any treatment emergent adverse event (TEAE)52254
At least one TEAE of special interest213
At least one serious TEAE310
At least one TEAE leading to dose modification24103
At least one TEAE leading to discontinuation421
SecondarySafety: Number of Patients Reporting Adverse Events up to Week 48

Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 48

Time frame:
From week 24 until week 48
Reported as:
Number · Number of participants
Safety: Number of Patients Reporting Adverse Events up to Week 48
Number of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Any TEAE506368461
At least one TEAE of special interest12240
At least one serious TEAE21251
At least one TEAE leading to dose modification152323211
At least one TEAE leading to discontinuation00020
SecondaryImmunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 24

Number of patients resulting positive to anti-tocilizumab antibodies test are reported.

Time frame:
From baseline to Week 24
Reported as:
Number · Number of participants
Immunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 24
Number of participantsPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Screen - Baseline613
Screen - Week 1212
Screen - Week 2439
Confirmatory - Baseline45
Confirmatory - Week 1210
Confirmatory - Week 2413
SecondaryImmunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 48

Number of patients resulting positive to anti-tocilizumab antibodies test are reported.

Time frame:
From week 24 until week 48
Reported as:
Number · Number of participants
Immunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 48
Number of participantsPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Screen - Week 360002—
Screen - Week 481323—
Confirmatory - Week 360001—
Confirmatory - Week 480001—
SecondaryImmunogenicity: TCZ Levels up to Week 24

Mean concentrations of TCZ in patients' blood are reported.

Time frame:
From baseline to Week 24
Reported as:
Mean · mcg/ml
Immunogenicity: TCZ Levels up to Week 24
mcg/mlPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline0.49 ± NA0.67 ± 0.34
Week 1237.97 ± 20.1141.23 ± 20.89
Week 2446.42 ± 28.3546.87 ± 27.65
SecondaryImmunogenicity: TCZ Levels at Week 36 and Early Withdrawal Visit

Mean concentrations of TCZ in patients' blood are reported.

Time frame:
week 36 and early withdrawal visit
Reported as:
Mean · mcg/ml
Immunogenicity: TCZ Levels at Week 36 and Early Withdrawal Visit
mcg/mlPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Week 3648.47 ± 30.1716.77 ± 16.1041.89 ± 28.8248.33 ± 25.79—
Early withdrawal visit36.45 ± 18.0319.20 ± NA24.43 ± 20.8313.75 ± 4.601.78 ± NA
SecondaryImmunogenicity: SIL-6R Levels up to Week 24

Mean concentration of SIL-6R in patients' blood are reported.

Time frame:
From baseline to Week 24
Reported as:
Mean · mcg/ml
Immunogenicity: SIL-6R Levels up to Week 24
mcg/mlPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline42.85 ± 16.2639.29 ± 11.10
Week 12566.47 ± 210.49570.34 ± 228.54
Week 24570.49 ± 198.26565.34 ± 198.32
SecondaryImmunogenicity: SIL-6R Levels at Week 36 and Early Withdrawal Visit

Mean concentration of SIL-6R in patients' blood are reported.

Time frame:
Baseline, Week 36 and Early Withdrawal Visit
Reported as:
Mean · mcg/ml
Immunogenicity: SIL-6R Levels at Week 36 and Early Withdrawal Visit
mcg/mlPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Baseline39.87 ± 10.4639.70 ± 16.4639.39 ± 11.2443.11 ± 11.8537.30 ± 11.46
Week 36539.89 ± 152.71476.28 ± 156.50542.99 ± 168.30552.65 ± 184.21—
Early withdrawal visit412.53 ± 323.49643.00 ± NA338.38 ± 230.82217.74 ± 236.21513.00 ± NA
SecondaryPatient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 24

This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.

Time frame:
From baseline to Week 24
Reported as:
Mean · Millimeters
Patient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 24
MillimetersPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline65.26 ± 19.7759.40 ± 17.61
Week 249.53 ± 22.7844.16 ± 21.97
Week 438.21 ± 22.9235.19 ± 20.83
Week 830.03 ± 21.6526.04 ± 20.59
Week 1222.71 ± 18.5622.24 ± 17.97
Week 1619.28 ± 18.2220.71 ± 18.65
Week 2016.80 ± 16.6818.79 ± 17.79
Week 2416.63 ± 15.1919.00 ± 18.36
LOCF visit20.36 ± 19.2522.23 ± 20.86
SecondaryPatient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 48

This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.

Time frame:
Baseline, from week 28 until week 48
Reported as:
Mean · Millimeters
Patient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 48
MillimetersPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline58.97 ± 17.4060.96 ± 20.13
Week 2811.97 ± 14.1012.74 ± 15.07
Week 3210.78 ± 15.3310.80 ± 11.36
Week 3611.99 ± 16.2310.30 ± 13.20
Week 4010.62 ± 13.4910.94 ± 14.12
Week 449.50 ± 11.3010.06 ± 12.14
Week 488.13 ± 10.529.99 ± 13.88
LOCF visit8.97 ± 11.6310.21 ± 13.96
SecondaryAssessment of Pain Reported by the Patient (VAS) Until Week 24

This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".

Time frame:
From baseline to Week 24
Reported as:
Mean · Millimeters
Assessment of Pain Reported by the Patient (VAS) Until Week 24
MillimetersPhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline66.38 ± 20.7058.59 ± 23.70
Week 253.20 ± 24.4347.46 ± 25.14
Week 443.11 ± 24.6942.88 ± 24.57
Week 835.95 ± 24.6234.28 ± 25.94
Week 1229.44 ± 22.3731.07 ± 24.97
Week 1632.17 ± 22.0130.18 ± 24.00
Week 2026.58 ± 22.1328.26 ± 24.16
Week 2423.56 ± 21.1726.43 ± 23.30
LOCF visit27.34 ± 24.4129.78 ± 25.18
SecondaryAssessment of Pain Reported by the Patient (VAS) Until Week 48

This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".

Time frame:
Baseline, from week 28 until week 48
Reported as:
Mean · Millimeters
Assessment of Pain Reported by the Patient (VAS) Until Week 48
MillimetersPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline55.73 ± 21.6856.00 ± 23.56
Week 2817.33 ± 20.1415.67 ± 17.65
Week 3217.08 ± 20.4717.27 ± 17.69
Week 3618.81 ± 23.8814.36 ± 15.65
Week 4016.96 ± 20.8917.07 ± 17.86
Week 4415.05 ± 18.0216.27 ± 17.70
Week 4811.90 ± 15.5616.31 ± 19.85
LOCF visit12.74 ± 15.9916.41 ± 19.76
SecondaryHealth Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 24

The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.

Time frame:
From baseline to Week 24
Reported as:
Mean · HAQ-DI score
Health Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 24
HAQ-DI scorePhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline1.49 ± 0.761.36 ± 0.70
Week 21.39 ± 0.741.18 ± 0.69
Week 41.20 ± 0.741.05 ± 0.69
Week 81.10 ± 0.750.95 ± 0.71
Week 120.99 ± 0.740.91 ± 0.71
Week 160.99 ± 0.720.87 ± 0.70
Week 200.88 ± 0.700.83 ± 0.71
Week 240.85 ± 0.710.82 ± 0.70
LOCF visit0.97 ± 0.760.88 ± 0.73
SecondaryHealth Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 48

The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.

Time frame:
Baseline, from week 28 until week 48
Reported as:
Mean · HAQ-DI score
Health Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 48
HAQ-DI scorePhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline1.21 ± 0.681.20 ± 0.70
Week 280.58 ± 0.560.57 ± 0.64
Week 320.55 ± 0.580.57 ± 0.63
Week 360.60 ± 0.600.56 ± 0.64
Week 400.55 ± 0.560.61 ± 0.67
Week 440.53 ± 0.570.58 ± 0.66
Week 480.53 ± 0.610.57 ± 0.66
LOCF visit0.55 ± 0.610.56 ± 0.66
SecondaryFunctional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 24

The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.

Time frame:
From baseline to Week 24
Reported as:
Mean · FACIT-F score
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 24
FACIT-F scorePhase 1: Tocilizumab MonotherapyPhase 1: Combination Therapy
Baseline81.72 ± 24.7589.16 ± 24.49
Week 286.64 ± 25.0095.82 ± 25.42
Week 492.26 ± 25.3099.54 ± 27.15
Week 896.45 ± 25.88103.46 ± 27.25
Week 1298.29 ± 25.47104.08 ± 26.79
Week 1698.41 ± 27.08105.51 ± 26.94
Week 20102.46 ± 27.24104.91 ± 27.47
Week 24104.36 ± 27.16107.01 ± 27.60
LOCF visit101.38 ± 28.24104.65 ± 28.07
SecondaryFunctional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 48

The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.

Time frame:
Baseline, from week 28 until week 48
Reported as:
Mean · FACIT-F score
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 48
FACIT-F scorePhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)
Baseline17.36 ± 5.1617.13 ± 5.67
Week 2823.50 ± 3.8223.12 ± 4.47
Week 3223.62 ± 4.1622.98 ± 4.86
Week 3623.23 ± 4.2122.90 ± 4.64
Week 4023.39 ± 4.4023.02 ± 4.38
Week 4423.48 ± 4.2123.13 ± 4.45
Week 4823.95 ± 3.7922.87 ± 4.87
LOCF visit23.69 ± 4.0722.88 ± 4.85

Adverse events

Collected over After initiation of study drug, all AEs, regardless of relationship to study drug, are reported until study closure.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Tocilizumab Monotherapy0/74 (0%)3/74 (4.1%)24/74 (32.4%)
Phase 1: Combination Therapy1/327 (0.3%)10/327 (3.1%)119/327 (36.4%)
Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)0/89 (0%)2/89 (2.2%)17/89 (19.1%)
Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)0/90 (0%)1/90 (1.1%)25/90 (27.8%)
Phase 2 Arm B: Participants With Low Disease Activity0/95 (0%)2/95 (2.1%)30/95 (31.6%)
Phase 2 Arm C: Moderate EULAR Response at Week 242/67 (3%)5/67 (7.5%)23/67 (34.3%)
Phase 2 Arm D: Non Responders0/2 (0%)1/2 (50%)0/2 (0%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPhase 1: Tocilizumab MonotherapyPhase 1: Combination TherapyPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
AscitesGastrointestinal disorders0/740/3270/890/900/950/671/2
Coronary artery diseaseCardiac disorders0/740/3270/890/900/951/670/2
Myocardial infarctionCardiac disorders0/740/3270/890/900/951/670/2
Spinal fractureInjury, poisoning and procedural complications0/740/3270/890/900/951/670/2
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/740/3270/890/900/951/670/2
Hypertensive crisisVascular disorders0/740/3270/890/900/951/670/2
PericarditisCardiac disorders1/740/3270/890/900/950/670/2
HeadacheNervous system disorders1/740/3270/890/900/950/670/2
Deep vein thrombosisVascular disorders1/740/3270/890/900/950/670/2
IleusGastrointestinal disorders0/740/3271/890/900/950/670/2
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPhase 1: Tocilizumab MonotherapyPhase 1: Combination TherapyPhase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w)Phase 2 Arm B: Participants With Low Disease ActivityPhase 2 Arm C: Moderate EULAR Response at Week 24Phase 2 Arm D: Non Responders
Transaminases increasedInvestigations1/7437/3270/890/900/950/670/2
Upper respiratory tract infectionInfections and infestations2/7423/3279/897/903/954/670/2
Urinary tract infectionInfections and infestations6/7423/3273/892/908/953/670/2
Injection site erythemaGeneral disorders6/7410/3270/890/900/950/670/2
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/740/3272/893/906/953/670/2
Oedema peripheralGeneral disorders0/740/3270/891/903/954/670/2
NasopharyngitisInfections and infestations0/740/3272/894/905/954/670/2
HeadacheNervous system disorders0/740/3272/891/900/954/670/2
NeutropeniaBlood and lymphatic system disorders4/7418/3271/895/903/952/670/2
NauseaGastrointestinal disorders1/7418/3270/890/900/950/670/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1: Tocilizumab MonotherapyPhase 1: Combination TherapyTotal
Mean53.5 ± 12.753.6 ± 12.253.6 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Tocilizumab MonotherapyPhase 1: Combination TherapyTotal
Female62264326
Male126375
08

Study locations

53 sites
  • Co Leitrim, Ireland
  • Cork, Ireland
  • Dublin 4, 4, Ireland
  • Dublin, 24, Ireland
  • Limerick, 0, Ireland
  • Waterford, Ireland
  • Almada, 2801-951, Portugal
  • Amadora, 3814-501, Portugal
  • Lisboa, 1050-34, Portugal
  • Lisboa, 1649-035, Portugal
  • Porto, 4099-001, Portugal
  • Porto, 4200-319, Portugal
  • Elche, Alicante 03203, Spain
  • Merida, Badajoz 06800, Spain
  • Sabadell, Barcelona 08208, Spain
  • Sant Joan Despi, Barcelona 08970, Spain
  • Terrassa, Barcelona 08221, Spain
  • Jerez de La Frontera, Cadiz 11407, Spain
  • Torrelavega, Cantabria 39300, Spain
  • San Sebastian, Guipuzcoa 20080, Spain
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • La Coruna, La Coruña 15006, Spain
  • Santiago De Compostela, La Coruña 15706, Spain
  • Las Palmas de Gran Canaria, Las Palmas 35016, Spain
  • Fuenlabrada, Madrid 28942, Spain
  • Cartagena, Murcia 30203, Spain
  • El Palmar, Murcia 30120, Spain
  • Valenica, Valencia 46009, Spain
  • Bilbao, Vizcaya 48013, Spain
  • Alicante, 03010, Spain
  • Barcelona, 08025, Spain
  • Barcelona, 08036, Spain
  • Burgos, 06006, Spain
  • Cordoba, 14004, Spain
  • Granada, 18014, Spain
  • Guadalajara, 19002, Spain
  • Madrid, 28006, Spain
  • Madrid, 28007, Spain
  • Madrid, 28034, Spain
  • Madrid, 28041, Spain
  • Madrid, 28046, Spain
  • Madrid, 28222, Spain
  • Madrid, 28905, Spain
  • Malaga, 29009, Spain
  • Salamanca, 37007, Spain
  • Sevilla, 41009, Spain
  • Sevilla, 41010, Spain
  • Sevilla, 41013, Spain
  • Tarragona, 43700, Spain
  • Tenerife, 38010, Spain
  • Toledo, 45004, Spain
  • Valencia, 46010, Spain
  • Zaragoza, 50009, Spain
09

References and documents

Publications

  • Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, Gonzalez C, Ercole L, Alonso R, Fonseca JE; ToSpace Study Group. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis Rheumatol. 2019 Oct;71(10):1616-1625. doi: 10.1002/art.40905. Epub 2019 Sep 24. PubMed 31087542 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jul 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2013
First posted
Nov 26, 2013
Start
Sep 2013
Primary completionActual
Jul 2015
CompletionActual
Mar 2016
Results first posted
Jan 26, 2018
Last update
Jan 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01995201
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Sep 2013
Primary completion
Jul 2015
Completion
Mar 2016
Results posted
Jan 26, 2018
Last update
Jan 26, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tocilizumab

Start the discussion